Narrative review / 2014
Lorcaserin and phentermine-topiramate produced modest weight loss alongside diet and exercise in trials, but carry serious safety warnings.
In 2012, the FDA approved lorcaserin and phentermine-topiramate based on 1-year trials alongside recommendations for a calorie-restricted diet and exercise. Patients lost more weight than those on placebo: 3% (95% CI, 3%-4%) more with lorcaserin and 7% (95% CI, 3%-4%) more with phentermine/topiramate. However, both drugs carry warnings for memory, attention, or language problems and depression, alongside other serious drug-specific harms. Neither drug is marketed in Europe due to safety concerns, and required postmarketing safety trials in the US are behind schedule.
- Study type
- Narrative review / commentary
- Who was studied
- Patients in 1-year clinical trials for weight loss
- What was measured
- Weight loss and drug-related harms/safety warnings
THE PAPER
The new weight-loss drugs, lorcaserin and phentermine-topiramate: slim pickings?
Woloshin S, Schwartz LM. JAMA Intern Med, 2014.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.